Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204826 | 0.80 | ALDH1A1 (0.43) | MAPTGAARAB9ASOAT1ALDH1A1 | |
| SCHEMBL20744302 | 0.79 | MAPT (0.31) | MAPTALDH1A1NPSR1GLO1TSHR | |
| SCHEMBL20744060 | 0.79 | MAPT (0.31) | MAPTALDH1A1NPSR1GLO1TSHR | |
| SCHEMBL12822512 | 0.79 | NPSR1 (0.32) | MAPTGAASOAT1ALDH1A1ALOX15 | |
| SCHEMBL6642281 | 0.78 | MAPT (0.47) | MAPTGAARAB9ASOAT1ALDH1A1 | |
| SCHEMBL2255510 | 0.77 | SOAT1 (0.39) | MAPTGAARAB9ASOAT1ALDH1A1 | |
| SCHEMBL884494 | 0.76 | MAPT (0.34) | MAPTGAAALDH1A1NPSR1GLO1 | |
| SCHEMBL962321 | 0.75 | GLO1 (0.47) | MAPTGAARAB9ASOAT1ALDH1A1 | |
| SCHEMBL15730012 | 0.75 | MAPT (0.44) | MAPTGAARAB9ASOAT1ALDH1A1 | |
| SCHEMBL14922478 | 0.73 | ALOX15 (0.44) | MAPTGAARAB9ASOAT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | claimed |
| CN-110724094-B | Quinoline compound and synthesis method thereof | 陕西科技大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-110724094-A | Quinoline compound and synthesis method thereof | 陕西科技大学 | 2020-01-24 | — | — | CN | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| EP-1991542-B1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| EP-1991542-B1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA LTD (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20100105665-A1 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100004128-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004128-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| EP-1991542-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | Syngenta Limited (GB) | 2008-11-19 | — | — | EP | disclosed |
| US-20080219924-A1 | Imaging, diagnosis and treatment of disease | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
| WO-2008089005-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007096576-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096576-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-5204333-A | Fluorine substituted heterobicycloalkanes | WELLCOME FOUNDATION LIMITED, THE (GB) | 1993-04-20 | — | — | US | disclosed |
| EP-0380312-A1 | Pesticidal compounds | ROUSSEL-UCLAF (FR) | 1990-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105665-A1 | RENIN INHIBITORS | REN, ACE, AGT | MAPT 2847/4885GAA 96/4885RAB9A 559/4885 |
| US-20100004128-A1 | HERBICIDAL ISOXAZOLINE COMPOUNDS | CYP4X1, RDX, HAX1 | MAPT 4065/4885GAA 1515/4885RAB9A 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.